Table 3.
Multivariable Cox regression analysis for event-free survival
| HR (EFS) | (95% CI for HR) | p-value | HR (OS) | (95% CI for HR) | p-value | |
|---|---|---|---|---|---|---|
| SULpeak | 1.0 | (1.0–1.1) | 0.36 | 1.0 | (0.9–1.1) | 0.9 |
| Staging (metastatic vs. localized) | 2.7 | (1.2–6.0) | 0.02a | 1.8 | (0.6–5.4) | 0.31 |
| Histologic response (poor vs. good) | 2.5 | (1.0–6.2) | 0.045a | 2.5 | (0.7–9.5) | 0.17 |
| TLGtotal | 1.0 | (1.0–1.0) | 0.75 | 1.0 | (1.0–1.0) | 0.84 |
| Staging (metastatic vs. localized) | 2.6 | (1.1–6.2) | 0.03a | 1.8 | (0.6–6.0) | 0.31 |
| Histologic response (poor vs. good) | 2.5 | (1.0–6.3) | 0.047a | 2.6 | (0.7–9.7) | 0.17 |
| MTVtotal | 1.0 | (1.0–1.0) | 0.17 | 1.0 | (1.0–1.0) | 0.92 |
| Staging (localized vs. metastatic) | 2.6 | (1.1–6.4) | 0.04a | 1.7 | (0.5–5.7) | 0.37 |
| Histologic response (good vs. poor) | 2.5 | (1.0–6.3) | 0.045a | 2.5 | (0.7–9.4) | 0.19 |
CI confidence interval, EFS event-free survival, HR hazard ratio, SUL standardized uptake value lean-body mass corrected, OS overall survival
a Indicates significance